research 31810 The National Paediatric Alopecia Areata Registry in Russia: An overview
The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
Search
for
Sort by
Research
900-930 / 1000+ results 
research Human papillomavirus vaccine recombinant quadrivalent
Two women lost hair after mesotherapy for hair loss, with one having permanent and the other temporary hair loss.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research Promising protocol for in vivo experiments with betulin
A new method improves betulin delivery in experiments, showing promise against certain tumors.
research Abstract SS02-02: Chemoprevention: Poised for Success
Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
research Prevention of chemotherapy-induced alopecia in rodent models
Localized heat or specific injections can prevent chemotherapy-induced hair loss without affecting cancer treatment.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Low-dose oral minoxidil for persistent chemotherapy and radiotherapy-induced alopecia in a pediatric female patient
research Electronic Brachytherapy for the Treatment of Nonmelanoma Skin Cancer: Results at 3 Years
High dose rate electronic brachytherapy is an effective and safe non-surgical treatment for nonmelanoma skin cancer with good cosmetic results after three years.
research Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
research Intradermal Local Injection of Autologous Cell‐Free Fat Extract for the Treatment of Refractory Postinflammatory Hyperpigmentation
CEFFE injections effectively and safely improve postinflammatory hyperpigmentation.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Finasteride-associated central retinal vein occlusion
research A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention
Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.
research Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
Nail changes from immunotherapy can be managed without stopping cancer treatment.
research Mogamulizumab‐induced alopecia. Multicentric case series: Clinical, trichoscopic and histological characterization
Mogamulizumab can cause hair loss, often linked to a better treatment response.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research Successful in situ 5-aminolevulinic acid photodynamic therapy in a 53-year-old female with cutaneous squamous cell carcinoma
Photodynamic therapy successfully treated skin cancer in a 53-year-old woman.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research Human placental mesenchymal stromal cell‐derived exosome‐enriched extracellular vesicles for chronic cutaneous graft‐versus‐host disease: A case report
Exosome-enriched vesicles from placental cells improved skin condition in a patient with chronic graft-versus-host disease.
research Unravelling a novel role for Cannabidivarin in the modulation of subventricular zone postnatal neurogenesis
Cannabidivarin (CBDV) helps new brain cells grow and develop in a specific brain area through a certain receptor.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Laminin-511, inducer of hair growth, is down-regulated and its suppressor in hair growth, laminin-332 up-regulated in chemotherapy-induced alopecia
Chemotherapy-induced hair loss is partly due to decreased laminin-511 and increased laminin-332.